Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Antigen-targeted nanoparticle tolerance therapeutics - AnTolRx

Next Previous
Drug Profile

Research programme: Antigen-targeted nanoparticle tolerance therapeutics - AnTolRx

Alternative Names: TNTT

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnTolRx
  • Developer AnTolRx; Pfizer
  • Class Anti-inflammatories; Antigens; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Coeliac disease; Inflammatory bowel diseases; Multiple sclerosis; Myasthenia gravis; Psoriasis; Rheumatoid arthritis; Skin disorders; Type 1 diabetes mellitus

Most Recent Events

  • 23 Sep 2025 Preclinical development is ongoing for Type-1-diabetes in the US (AnTolRx pipeline, September 2025)
  • 28 Sep 2024 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA
  • 22 Sep 2022 Preclinical development is ongoing for Type-1 diabetes mellitus in USA (AnTolRx pipeline, September 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top